Weed Inc (OTCMKTS:BUDZ) is a penny play that has started to engage some focus among traders and investors as prices get a little traction in bounce mode. The stock was a big flavor of the day back in January, flying about 900% higher in a month. It has subsequently given up all of those gains. However, upon reaching that same original level around $0.40-0.50/share, support was hit and the stock went full blast into bounce mode, more than doubling over the past couple sessions.
The company’s most recent key catalyst is its announcement of the acquisition of Sangre AT, LLC as a wholly-owned subsidiary of WEED. According to company materials, Sangre AgroTech has begun its 5-Year, $10 million Cannabis Genomic Study to complete a global genomic classification of the Cannabis plant genus. “We are pleased to be able to finally make this announcement,” said WEED’s Co-Founder and CEO, Glenn E. Martin. “It’s been in the works for several months now.”
Weed Inc (OTCMKTS:BUDZ) promulgates itself as a company that seeks to pursue full legalization of cannabis across America through a legal taxation with representation format.
The company is a USA-based public firm. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand.
WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law in the countries that WEED does business in.
According to company materials, “is a public company, trading on the Over The Counter quotation system. Investors and shareholders may view WEEDS stock info at OTCMarkets,com WEED will focus on purchasing land and building Commercial Grade “Cultivation Centers” to consult, assist, manage & lease to Licensed Dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. Once cleared off the Schedule 1 of the Controlled Substance Act. WEED will look to purchase and/or establish its own wholesale/retail outlets. “RESEARCH is the KEY to the FUTURE”. To that effect WEED will open a Research Center in Perth Australia in Q1 2016..”
Subscribe below and we’ll keep you on top of what’s happening before $BUDZ stock makes its next move.
As noted above, the company just announced the acquisition of Sangre AgroTech, who specializes in “next generation sequencing” instruments, but also emerging sequencing technologies that are currently restricted to key “decision maker” laboratories.
In addition, Sangre AgroTech utilizes the most advanced proprietary bioinformatics data systems available. The combination of personnel, skill-sets, and data analytics capabilities will allow Sangre to accomplish its goals in months, rather than years. “The Sangre AgroTech research team is honored to be a part of WEED Inc.,” said Dr. Williams, “and to have the opportunity to perform this ground-breaking research which will contribute to the resolution of human disease for years to come.”
The chart shows just shy of 140% during the past week in terms of shareholder gains in the stock, but that move comes in the context of a larger bearish trend. Market participants may want to pay attention to this stock. BUDZ has evidenced sudden upward volatility on many prior occasions. What’s more, the company has registered increased average transaction volume recently, with the past month seeing topping 220% beyond its prior sustained average level.
Traders should note this as important given the stock’s tiny trading float of 43M shares. Traders should not overlook this combination, as ramping trading activity can overwhelm available supply in a stock with this type of small float, leading to an upward burst in prices.
At this time, carrying a capital value in the market of $131.1M, BUDZ has virtually no cash on the books, which stands against about $279K in total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $BUDZ stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!